Literature DB >> 20082987

The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.

Mats I Ekstrand1, Dagmar Galter.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by selective and progressive degeneration of dopamine neurons in the substantia nigra. While most cases are sporadic a few rare familial forms of PD have been described. Several lines of evidence indicate that mitochondrial dysfunction may be involved in the etiology of the disease. Genes found to cause familial Parkinsonism have been linked to mitochondrial function and toxins that inhibit the mitochondrial respiratory chain have been found to cause dopamine cell death. Furthermore, higher numbers of respiratory chain deficient dopamine neurons are found in patients with PD than in age-matched controls. The MitoPark mouse model of PD was designed to directly test the hypothesis that mitochondrial dysfunction in dopamine neurons can cause a progressive parkinsonian phenotype. By cell type-specific inactivation of mitochondrial transcription factor A, a protein essential for mitochondrial DNA expression and maintenance, dopamine neurons were rendered respiratory chain deficient. MitoPark mice recapitulate several features of PD in humans such as adult-onset degeneration of nigrostriatal dopamine circuitry; motor deficits that are ameliorated by L-DOPA administration; progressive course of phenotypic manifestations and neurodegeneration; and altered response to L-DOPA treatment dependent on disease stage. In this review we compare the MitoPark mouse to other genetic or toxin-based rodent models of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20082987     DOI: 10.1016/S1353-8020(09)70811-9

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  46 in total

1.  Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors.

Authors:  Yuan-Hao Chen; Tsung-Hsun Hsieh; Tung-Tai Kuo; Jen-Hsin Kao; Kuo-Hsing Ma; Eagle Yi-Kung Huang; Yu-Ching Chou; Lars Olson; Barry J Hoffer
Journal:  J Neurochem       Date:  2019-05-09       Impact factor: 5.372

2.  Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.

Authors:  Monica R Langley; Shivani Ghaisas; Muhammet Ay; Jie Luo; Bharathi N Palanisamy; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2017-06-20       Impact factor: 4.294

3.  A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.

Authors:  Brian P Dranka; Alison Gifford; Donna McAllister; Jacek Zielonka; Joy Joseph; Crystal L O'Hara; Cheryl L Stucky; Anumantha G Kanthasamy; Balaraman Kalyanaraman
Journal:  Neurosci Lett       Date:  2014-09-26       Impact factor: 3.046

Review 4.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

5.  Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.

Authors:  William B Lynch; Christopher W Tschumi; Amanda L Sharpe; Sarah Y Branch; Cang Chen; Guo Ge; Senlin Li; Michael J Beckstead
Journal:  Mov Disord       Date:  2018-11-15       Impact factor: 10.338

6.  MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Authors:  Steven M Grauer; Robert Hodgson; Lynn A Hyde
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

Review 7.  Mitochondrial genome changes and neurodegenerative diseases.

Authors:  Milena Pinto; Carlos T Moraes
Journal:  Biochim Biophys Acta       Date:  2013-11-16

Review 8.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

Review 9.  Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson's Disease.

Authors:  Jie Luo; Piyush Padhi; Huajun Jin; Vellareddy Anantharam; Gary Zenitsky; Qian Wang; Auriel A Willette; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2019-03-16       Impact factor: 4.147

Review 10.  Aberrant features of in vivo striatal dynamics in Parkinson's disease.

Authors:  Kwang Lee; Sotiris C Masmanidis
Journal:  J Neurosci Res       Date:  2019-09-09       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.